Home Tags Anti-HER2 ADC SYD985

Tag: Anti-HER2 ADC SYD985

The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...

Mark Frigerio, Ph.D.
Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...

Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...

Peter Hofland
Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X